NWBO: Once In A Decade Best Stock Investment -- Regulatory Approvals Coming! [Dec10, 2022 在第一页加了中文简述]

Since the filing of PRE 14A there have been rampant speculations on various possibilities besides the items to vote for which are listed in the Preliminary Proxy Statement. Nothing is wrong with that, and that is the nature of retail investors (mostly sheep, not really having the conviction based on adequate and effective DDs).

As of this time after the results were validated with JAMA Oncology and the increased awareness of the breakthrough achievements for both nGBM and rGBM for decades, there has been an increased consensus DCVax-L (murcidencel) will be approved by all RAs concerned.

So no matter whether there is(are) partnership(s) or eventually a buyout, and when these events will happen, is actually not really important, because times and times again it has shown timing the market, particularly in a short term never is a smart investing idea.

If one believes the vaccine will be eventually approved, and price at this range (market cap around $1 billion) is at or near the bottom. It will be easy to handle price volatility. Proportionally start a new position for newbies, or add more whenever the price is surpressed, or simply hold, no need to give a shit on any short-term price fluctuation.

What will happen will happen: Commercial manufacturing license for UK facility, BLA submissions/acceptances with PDUFA days, RAs approvals, with partnerships or buyout that may come either before or amid/after the above events.

On the other hand, at some point down the road the short will give in their fights because the fights are futile. No need to try to time it. I would consider it a sweet bonus or reward when it happens, and I believe it will happen.
 
最后编辑:
1669648065228.png
1669648124730.png
 
As said in this threat before, long-term investors shall look beyond the approval of DCVax-L for GBM. It will be a fascinating story to witness, participate and forever to remember.
1669728451912.png
 
Selling subsided, simple change of the supply and demand trend.

1669819187356.png
 
Great, first lawsuit launched against the corrupted criminal market manipulator cabal:

www.wsj.com

WSJ News Exclusive | Biotech Company Says Citadel Securities, Other Big Traders Manipulated Its Stock Price

In a new lawsuit, Northwest Biotherapeutics accused market makers of illicit “spoofing” orders.
www.wsj.com www.wsj.com

Biotech Company Says Citadel, Other Big Traders Manipulated Its Stock Price​

In a new lawsuit, Northwest Biotherapeutics accuses market makers of illicit ‘spoofing’ trades​


A biotechnology company accused Citadel Securities LLC, Susquehanna International Group LLP and other Wall Street firms of driving down its stock price through a series of illicit trades.

In a lawsuit filed Thursday in Manhattan federal court, Northwest Biotherapeutics Inc. NWBO -2.15%decrease; red down pointing triangle

alleged the market makers had repeatedly engaged in “spoofing,” where traders place orders with an intent to fool other investors about a stock’s demand and manipulate the price.

Northwest, whose shares trade over the counter, also sued Canaccord Genuity Inc., CF 3.06%increase; green up pointing triangle
G1 Execution Services LLC, GTS Securities LLC, Instinet LLC, Lime Trading Corp. and Virtu Americas LLC.

Spokesmen for Citadel and Virtu didn’t immediately comment. The other firms didn’t immediately respond to requests for comment.

Spoofing, which was outlawed in 2010, has been at the center of a yearslong campaign by U.S. authorities to root out market manipulation. In August, a federal jury in Chicago convicted two former JPMorgan Chase & Co. traders who had been charged with spoofing in the gold market.

In the modern stock market, high-speed trading firms like Citadel and Susquehanna provide stock quotes throughout the day, executing orders from other investors while collecting a thin spread between the buying and selling price of the shares.

It’s unclear from the data cited in the suit whether the alleged spoofing trades were placed on behalf of other investors, or by the firms themselves.

But Northwest argued that these market makers knew it was unlawful to execute the alleged trades and should have had procedures in place to detect and prevent them.

The market makers, Northwest wrote, “deliberately engaged in repeated spoofing that interfered with the natural forces of supply and demand and drove (the company’s) share price downward over the course of the relevant period.”

Northwest said the alleged spoofing trades, which occurred between December 2017 and August 2022, battered the stock price even as the company released positive results from the trial of its lead product, a brain cancer treatment. In its suit, the company wrote that it had sold more than 49 million shares to raise money “at artificially depressed prices.”

“One of the tell-tale signs of a manipulative spoofer is a rapid reversal of trading direction — a lot of sell orders, followed by buy orders, followed by the cancellation of sell orders — which suggest the original sell orders were not intended to be executed, but were merely a ploy to drive the price down to `buy low,’” Northwest said in its complaint.

The company said it found thousands of spoofing episodes involving tens of millions of “baiting orders” over a five-year span, and was able to identify the market participants using trading data.
 
最后编辑:
Henri 说:
Lawsuit will likely take years.
遠水救不了近火。
We need Reddit crowd.
点击展开...
You are right Henri. The positive things about this lawsuit is its deterrence to those corrupted factions in the Wall Street that their illegal actions are watched and will be panelized; in the meantime, the lawsuit in and of itself has become a widespread news, which raises awareness about our plight of putting a life-saving, a potential paradigm shift cancer treatment/curing platform into actually saving patients lives and also the most corrupt forces who care nothing but their own interests who tried to bankrupt this company and when that failed, today still try to impede the development and commercialization of the underlining cancer treatment/curing platform: DCVax. So all in all, it's a huge positive.

One other positive is it revealed the company is now ready to fight, walking out of its self-imposed long quiet period. So when somebody punches the company, the company will fight back.

This lawsuit when it is done will potentially bring several hundreds of millions penalty to those accused, if not 1 billion or more (on May 10 alone, a billion was shed from company's market cap due to the illegal price supression of these accused MMs.

I like the awareness part the most as we are waiting for ASM proxy material, and who knows what good news will it brings in days ahead.
 
最后编辑:
Since the launch of lawsuit, short borrowing rate has increased significantly while shorted shares ratio has decreased below 50%

1670032715134.png


1670032754799.png
 
The stake is high

News Article

Al's Comment:
" People always ask me why Northwest Biotherapeutics' stock didn't skyrocket when they released fantastic news that their phase 3 clinical trial was a complete success. It made people think there was something wrong, and unless you read the full publication along with the supplemental materials which clearly answers all of the negative comments floating around about the trial, you might be tempted to believe some of the misleading articles that were published about the trial. This article talks about the main reason why the stock is so low and has gone lower every time the company announced good news. It is probably (innocent until proven guilty) because of stock manipulation by a few greedy companies who care more about money than your lives. This scam has delayed the approval of DCVAX by years - killing many people who might have been saved. Hopefully this ends now, and we can get back to finding the cure! "
 
您必须登录或注册才可回复。
后退
顶部